Nyrada Inc. (NYR.AX)
- Previous Close
0.0960 - Open
0.0980 - Bid 0.0940 x 2307600
- Ask 0.0960 x 3000000
- Day's Range
0.0940 - 0.0980 - 52 Week Range
0.0180 - 0.1700 - Volume
1,351,825 - Avg. Volume
4,946,288 - Market Cap (intraday)
16.864M - Beta (5Y Monthly) 1.53
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurodegenerative diseases. Its products in the drug development stage includes PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce the disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.
www.nyrada.comRelated News
Performance Overview: NYR.AX
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYR.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYR.AX
Valuation Measures
Market Cap
16.86M
Enterprise Value
12.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.54
Financial Highlights
Profitability and Income Statement
Profit Margin
-169.82%
Return on Assets (ttm)
-40.53%
Return on Equity (ttm)
-72.31%
Revenue (ttm)
2.93M
Net Income Avi to Common (ttm)
-4.98M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
4.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.83M
Company Insights: NYR.AX
NYR.AX does not have Company Insights